35 results about "S-Nitrosoglutathione" patented technology

The invention describes novel nitrosated and / or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and / or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and / or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The invention discloses a method for constructing an anti-blood coagulation blood vessel scaffold material by utilizing an endogenous NO donor. The method comprises the steps that organic selenium polycation high polymer and polyanion high polymer are alternately coated on the surface of the blood vessel scaffold material in sequence through a layer-by-layer self-assembled method to form a blood vessel scaffold material surface decorated by a multilayer bimolecular film, thus catalyzing the endogenous NO carries such as S-nitroso glutathione (GSNO) existing in the body, realizing sustained and partial release of NO, effectively regulating and controlling the release rate of NO by regulating and controlling the number of layers of the layer-by-layer self-assembled bimolecular film, and further improving blood coagulation resistance of the blood vessel scaffold material. The method of the invention can be used for metal blood vessel scaffolds or organic polymer artificial blood vessel scaffolds or cell-free artificial blood vessel scaffolds, and also can be used for other medical appliances contacting with blood.

The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNOg to increase VE in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the equivalent increases in VE, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The invention provides stable S-nitrosothiol, such as S-nitrosoglutathione, formulations for long term storage and in vivo delivery of S-nitrosothiols. The invention provides stable aerosol formulations comprising S-nitrosothiol, such as S-nitrosoglutathione, and methods of treating patients in need of S-nitrosothiol, such as S-nitrosoglutathione, and / or nitric oxide treatment.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The invention relates to pharmaceutical compositions comprising S-nitrosoglutathione and one or more polysaccharide-type polimer(s) together with one or more pharmaceutically accepted polymer(s) and additive(s). The invention is based on the discovery that polysaccharide-type polymers (such as chitosan) are capable of stabilizing the otherwise highly labile GSNO.

The invention relates to the technical field of biomedical materials, and provides a nitride oxide nanocomposite hydrogel. The nitride oxide nanocomposite hydrogel is constituted by S-nitrosoglutathione (GSNO) loaded Eudragit RS PO nano suspension and a gel matrix in a mixed mode, the gel matrix is prepared from sodium alginate, a calcium chloride solution and glycerin, and mixed gel contains nanoparticles with Eudragit RS PO loaded with GSNO. The invention further provides a preparation method of the nitride oxide nanocomposite hydrogel and application of the nitride oxide nanocomposite hydrogel in the field of the biomedical materials. According to the nitride oxide nanocomposite hydrogel, aiming at two critical periods of the inflammation period and the proliferation period in skin wound healing, the nitric oxide nanocomposite hydrogel is constructed by taking the sodium alginate as a matrix phase and taking the nanoparticles with the Eudragit RS PO loaded with nitric oxide donor GSNO as a dispersion phase, nitric oxide is released at the wound part, thus generating of angiogenesis and generating of fibroblast in the inflammation period of wound repair are promoted, and generating of collagenous fibers in the proliferation period is promoted, so that the purpose of effectively promoting skin wound healing is achieved.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and / or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

The invention relates to pharmaceutical compositions having alkaline pH comprising S-nitrosoglutathione (GSNO) as active ingredient together with usual additives, optionally with one or more polysaccharide-type polymer(s). Another subject of the invention is a method for stabilizing a solution or non-solid composition containing GSNO wherein the pH of the solution or composition is adjusted to an alkaline value.

The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

The present invention is directed to novel dihydropyridin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors and / or Neurokinin-3 (NK3) receptor antagonists, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

A process for determining S-nitrosothiols, in particular S-nitrosoglutathione, in biological fluids that is easy, selective, cheap with respect to the prior art, which requires the use of equipment commonly available in laboratories, at low cost, which can be used by not qualified operators. The process is based on the hydrolysis of S-nitrosoglutathione (GSNO) by an enzyme, in particular γ-glutamyltranspeptidase (GGT). This enzyme hydrolizes the residual γ-glutamyl of GSNO for giving glutamate (GIu) and S-nitroso-cysteinylglycine (GIyCySNO). In the presence of ions of transition metals GGT speeds up the release of NO since the intermediate that is formed, the GIyCySNO, is much more sensitive to a metal-dependent decomposition. Advantageously, the amount of nitric oxide present in the sample is measured through a reaction thereof with 4,5 diaminof luorescein (DAF-2), said reaction creating a fluorescent compound in an amount proportional to the S-nitrosothiol amount present in the sample. Alternatively, the amount of released NO can be measured by a chemiluminescence analyser, commercially available. In the presence of biological fluids having complex matrix, the introduction of the enzyme is done after separation of the S-nitrosothiol from the other components of the fluid.

Disclosed herein are methods and compositions for modulating the levels and / or activity of S-nitrosoglutathione reductase (GSNOR) in vivo or in vitro. Specifically disclosed are GSNOR deletion constructs, host cells and non-human mammals comprising GSNOR deletions, and methods of screening employing GSNOR deletion mutants. Also specifically disclosed are reagents and procedures for measuring, monitoring, or altering GSNOR levels or activity (as well as nitric oxide and S-nitrosothiol levels) in connection with various medical conditions.

This invention provides a method of sterilising an S-nitrosothiol, for example S-nitrosoglutathione, without reduction of purity by more than about 5.0% through degradation. The invention allows sterile S-nitrosothiol or a sterile pharmaceutical pre-composition comprising S-nitrosothiol, wherein the S-nitrosothiol is in dry solid form, to be produced. The sterile pharmaceutical pre-composition is mixed with one or more diluents, excipients, carriers, additional active agents, or any combination thereof, for example sterile saline, to prepare a pharmaceutical composition of S-nitrosothiol for use.

The invention discloses novel application of S-nitrosoglutathione reductase genes of tomatoes. The S-nitrosoglutathione reductase genes can be used for preparing transgenic plants with enhanced nitrate resistance, NaCl resistance and drought stress resistance. The novel application has the advantages that plant expression vectors pRI101-GFP-SIADH3 are constructed by the aid of coding region sequences of the genes SIADH3 and are transferred into tobaccos by the aid of agrobacterium-mediated methods to be excessively expressed, and accordingly the nitrate resistance, the NaCl resistance and the drought stress resistance of the transgenic tobaccos can be obviously improved.

A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

The invention discloses a shelf fresh-keeping combined treatment method for semen trigonellae fruits. Beta-aminobutyric acid spray coating before harvesting and S-nitrosoglutathione fumigation treatment after harvesting are carried out, and enclosing packaging technology with certain air permeability and gamma irradiation technology are combined to realize the purpose, so that the shelf life of semen trigonellae fruits at room temperature or 4-5DEG C can be significantly prolonged, and the semen trigonellae fruits also can maintain good hardness, flavor and nutritional quality.

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.